Gesundheitsökonomie & Qualitätsmanagement, Inhaltsverzeichnis Gesundheitsökonomie & Qualitätsmanagement 2014; 19(4): 146-147DOI: 10.1055/s-0033-1362748 Herausgeberkommentar © Georg Thieme Verlag KG Stuttgart · New York Herausgeberkommentar – Warum prospektive und kontrollierte Studien? Erland Erdmann Artikel empfehlen Abstract Artikel einzeln kaufen Volltext Referenzen Literatur 1 Bhatt MD et al. A Controlled Trial of Renal Denervation for Resistant Hypertension. NEJM 2 Krum H et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281 3 Benson H et al. Angina pectoris and the placebo effect. NEJM 1979; 300: 1424-1429 4 Lange RA et al. Transmyocardial Laser Revascularisation. NEJM 1999; 341: 1075-1076 5 Connolly SJ et al. Dronedarone in High-Risk Permanent Atrial Fibrillation. NEJM 2011; 365: 2268-2276 6 Schwartz GG et al. Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. NEJM 2012; 367: 2089-2099 7 Lincoff M et al. Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus The AleCardio Randomized Clinical Trial. JAMA 3321 8 Ioannidis, J. Why Most Published Research Findings Are False. PLoS Medicine 2005; 2: 696-701
